Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Elaeagnus angustifolia pollen, derived from the Russian olive tree, is utilized primarily as an allergen extract for the diagnosis and treatment of Type I hypersensitivity reactions. In diagnostic applications, such as skin prick testing, the extract cross-links allergen-specific IgE on the surface of mast cells, triggering degranulation and a visible wheal-and-flare reaction. For therapeutic purposes, it is employed in allergen immunotherapy (AIT) to induce clinical and immunological tolerance. The mechanism involves shifting the immune response from a Th2-dominated profile to a Th1-dominated profile, increasing the production of regulatory T cells (Tregs), and stimulating the synthesis of allergen-specific IgG4 "blocking" antibodies. It is a significant aeroallergen in regions where the plant is invasive or widely cultivated, such as the Middle East and the Western United States.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on elaeagnus angustifolia pollen.